The Claim
Combination therapy with photodynamic therapy and aflibercept does not demonstrate statistically significant superiority over aflibercept monotherapy in improving best-corrected visual acuity or reducing central subfield thickness in treatment-naïve patients with polypoidal choroidal vasculopathy.
What the research says
Challenges is higher
Challenge is ahead, but a single strong supporting study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with polypoidal choroidal vasculopathy who have not received prior treatment, combining photodynamic therapy with aflibercept does not result in better improvement of vision or greater reduction in retinal swelling compared to aflibercept alone.
See the scientific wording
Combination therapy with photodynamic therapy and aflibercept does not demonstrate statistically significant superiority over aflibercept monotherapy in improving best-corrected visual acuity or reducing central subfield thickness in treatment-naïve patients with polypoidal choroidal vasculopathy, suggesting differential efficacy between anti-VEGF agents when combined with PDT.
Aflibercept blocks all VEGF signals that cause abnormal blood vessels to leak fluid into the retina. Adding PDT closes some of these vessels, but since aflibercept already stops the leakage completely, closing more vessels doesn't improve vision or reduce fluid any further.
What the research says
1 studyThe study found that combining PDT with eye injections (like aflibercept) works better than injections alone for improving vision and reducing fluid in the eye. This means the claim that adding PDT doesn’t help is wrong.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.